Photo of Harold Dutton
D Texas House · District 142 On the 2026 ballot

Rep. Harold Dutton

Compare
Total votes
8,331
all sessions
Attendance
88%
1,026 missed
Lower than 94% of chamber peers
With party
95%
of cast votes
Higher than 79% of chamber peers
Bipartisan score
3%
crosses aisle rarely
Lower than 83% of chamber peers
Sponsored
736
bills & resolutions
Near the chamber average
Committees
2
assignments
8,331 roll-call votes

Voting record

Yea
6,825
voted in favor
Nay
499
voted against
Absent
1,026
missed votes
Total cast
8,331
across all sessions
Crossed party
325
votes against own party
This page
8,331
matching current filters
Bill
Description
Vote
Result
Tally
Date
HB 3449
Relating to the reimbursement of expenses to certain counsel appointed to represent a defendant in a criminal proceeding.
Yea
Passed
135–1
May 13, 2025
HB 2464
Relating to the authority of a municipality to regulate a home-based business.
Absent
Passed
115–15
May 13, 2025
HB 3722
Relating to the height of a structure near certain airspace designated for use by Department of Defense contractors.
Nay
Passed
91–49
May 13, 2025
HB 2253
Relating to the authority to cancel certain elections on a measure to authorize the issuance of bonds.
Yea
Passed
98–38
May 13, 2025
HB 1533
Relating to the system for appraising property for ad valorem tax purposes.
Yea
Passed
137–0
May 13, 2025
HB 40
Relating to the business court. Against party
Yea
Passed
99–40
May 13, 2025
HB 1052
Relating to health benefit plan coverage of telemedicine, teledentistry, and telehealth appointments with an originating site or distant site located outside this state.
Yea
Passed
114–26
May 13, 2025
HB 4580
Relating to the exemption from ad valorem taxation of property owned by certain nonprofit corporations and used to promote agriculture, support youth, and provide educational support in the community.
Yea
Passed
102–33
May 13, 2025
HB 4755
Relating to the authority of certain municipalities to use hotel occupancy tax revenue for certain venue projects.
Yea
Passed
96–27
May 13, 2025
SB 2308
Relating to the establishment of a consortium to conduct United States Food and Drug Administration's drug development clinical trials with ibogaine to secure the administration's approval of the medication's use for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy and to the administration of that treatment.
Yea
Passed
138–1
May 13, 2025
Showing 1,681 to 1,690 of 8,331 votes